Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis

  • Campbell J
  • Lowe D
  • Sleeman M
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Rheumatoid arthritis is one of the commonest autoimmune diseases affecting 0.8% of the population. Over the last decade the treatment of this chronic disease has been revolutionized by the use of monoclonal antibodies and fusion proteins, targeting molecules like tumour necrosis factor alpha. Nevertheless, approximately one-third of subjects fail to respond to these therapies and therefore significant unmet medical need remains. Following a decade of use, clinical, government and regulatory agency expectations have changed for new antibodies therapies entering this highly competitive area. In this review, we discuss the current advances being made in antibody engineering and how they are being considered and used in the development of the next generation of antibodies to meet future expectations of healthcare providers, physicians and patients. Moreover, we discuss how pattern recognition receptors may provide new antibody tractable targets that may break the cycle of autoimmunity in rheumatoid arthritis. © 2011 MedImmune Ltd. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Author-supplied keywords

  • Animals
  • Antibodies
  • Arthritis
  • Autoimmunity
  • B lymphocyte
  • HLA DR1 antigen
  • Humans
  • Monoclonal
  • NCT00578682
  • NCT00946699
  • Pattern Recognition
  • Protein Engineering
  • Receptors
  • Rheumatoid
  • abatacept
  • adalimumab
  • amino terminal sequence
  • antibody structure
  • antigen binding
  • autoimmunity
  • certolizumab pegol
  • drug bioavailability
  • drug effects
  • drug efficacy
  • drug half life
  • drug safety
  • drug structure
  • etanercept
  • gene frequency
  • genetic association
  • genetics
  • glycosylation
  • golimumab
  • human
  • immunogenicity
  • immunology
  • infliximab
  • innate immunity
  • molecular biology
  • monoclonal antibody
  • mutagenesis
  • nonhuman
  • ofatumumab
  • pathology
  • priority journal
  • protein domain
  • protein modification
  • review
  • rheumatoid arthritis
  • rituximab
  • therapeutic use
  • therapy
  • tocilizumab
  • tru 015
  • tumor necrosis factor
  • unclassified drug

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jamie Campbell

  • David Lowe

  • Matthew A Sleeman

  • Campbell J.

  • Lowe D.

  • Sleeman M.A.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free